WO1997047285A1 - Gastric-retentive oral controlled drug delivery system with enhanced retention properties - Google Patents
Gastric-retentive oral controlled drug delivery system with enhanced retention properties Download PDFInfo
- Publication number
- WO1997047285A1 WO1997047285A1 PCT/US1997/009245 US9709245W WO9747285A1 WO 1997047285 A1 WO1997047285 A1 WO 1997047285A1 US 9709245 W US9709245 W US 9709245W WO 9747285 A1 WO9747285 A1 WO 9747285A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- single dosage
- sustained
- accordance
- release oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Definitions
- This invention is in the general field of pharmacology, and relates in particular to formulations that provide drugs with controlled release and that are retained in the stomach for a prolonged period of time.
- sustained release offers further advantages, particularly in the treatment of local disorders of the stomach.
- the treatment of esophageal reflux disease, the eradication of ulcer-causing bacteria in the gastric mucosa, and the need for sustained antacid action all benefit from sustained drug release in the stomach.
- Sustained release in the stomach also enhances the absorption of agents that are not readily absorbed, by prolonging their time of contact at absorption sites in the stomach or the upper part of the small intestine where the absorption area or contact time is normally limited.
- material passes through the small intestine, for example, in as little as 1.3 hours, and this time becomes critical for agents, such as captopril and the cephalosporins, that are absorbed almost exclusively at this site.
- these drugs must be administered either by injection or in frequent oral doses.
- a delivery system for these drugs that is retained in the stomach for a prolonged period of time feeds the drugs to the small intestine in a continuous and prolonged manner, thereby giving them more contact time at the sites where they are most readily absorbed.
- the fed mode is distinguished from the fasting mode, which prevails during nighttime rest and into the early morning hours.
- the fasting mode is characterized by interdigestive migrating motor complex (MMC) waves, which are a series of intense contractions beginning midway down the stomach and continuing down the intestinal tract to the distal ileum, clearing the stomach of digested materials as well as indigestible solids within a certain size range that would be retained if the stomach were in the fed mode.
- MMC interdigestive migrating motor complex
- the fed mode is then initiated by the ingestion of food, and entails a suspension of the MMC waves, thereby permitting the stomach to retain the particulate matter long enough to break it down and at least partially digest it.
- the MMC waves of the fasting mode resume but larger particulate matter is still retained by the stomach, the threshold size for the fasting mode being considerably larger than that for the fed mode.
- the fed mode can be induced by the presence of food, possibly from either of two signals, one that is believed to stem from stomach distension and the other, a much stronger chemical signal, that is known to be based on nutrient and osmotic factors. These factors include hypertonic solutions, acid, fat, certain carbohydrates, and certain amino acids. Fat is the most powerful of these factors, relaxing the fundus with lower intragastric pressure, increasing the reservoir function of the proximal stomach, contracting the pyloric sphincter, and changing intestinal peristalsis from a propagated series of waves to segmenting activity. Particles retained in the stomach due to their size could be a means of achieving prolonged retention in the stomach.
- the fed mode is normally provided by ingestion of a meal
- the use of a meal- induced fed mode as a means of prolonging the presence of a drug in the stomach has its disadvantages.
- One disadvantage is that the varying compositions of meals taken by different individuals make this approach unreliable.
- Another is that many drugs are adversely influenced by the presence of food in the stomach. Thus, while it increases the absorption of some drugs, it decreases the absorption of others.
- the fed mode as a means of sustaining gastric retention requires that the drugs be formulated in particles of a size large enough to be retained.
- the particles must retain their size while the drug dissolves in the gastric fluid so that dissolution of the drug does not by itself impair the controlled-release capabilities of the formulation.
- the quantity of drug in the formulation should be controllable independently of the particle size. There should be no need for example for the patient to ingest a large number of particles each of which is above the minimum size required for retention in the stomach.
- the present invention resides in a sustained-release drug delivery system that combines the benefits of swellable particles with a pharmacologically induced fed mode to retain the drug delivery system in the stomach of the patient independently of the dietary habits or digestive cycles of the patient. Drug administration is thereby achieved with a high level of control over the site of drug delivery.
- the delivery system of this invention is a single dosage form for oral administration that includes both a solid-state drug dispersed or otherwise retained in a solid matrix of a water-swellable polymer, and a chemical agent that pharmacologically induces the fed mode.
- the water-swellable polymer matrix is in the form of particles that are small enough for oral administration yet rapidly swell upon imbibition of water from gastric fluid to a size sufficiently large that they are retained in the stomach for several hours even after the fed mode has passed and the MMC waves have resumed.
- the swollen particles maintain their size long enough to hold the particles in the stomach for the desired duration of drug delivery, which is generally in excess of several hours.
- the matrix may thus be susceptible to decomposition by the action of components in the gastric fluid, or it may tend to dissolve in the gastric fluid, but in either case at a rate slow enough to maintain the retention-promoting size of the matrix particles for the desired duration.
- the drug itself is soluble in the gastric fluid, yet is released from the matrix into the fluid at a limited rate due to the characteristics of the swollen matrix.
- the chemical agent inducing the fed mode is immediately released, at least in part, to the gastric environment, thereby inducing the fed mode as soon as the dosage form reaches the stomach.
- the water-swellable matrix that retains the drugs in accordance with this invention is any polymer that is non-toxic, swells in a dimensionally unrestricted manner upon imbibition of water, and provides for sustained release of an incorporated drug.
- these polymers are cellulose polymers and polyalkylene oxides.
- cellulose is used herein to denote a linear polymer of anhydroglucose.
- Preferred cellulose polymers are alkyl-substituted cellulose polymers that ultimately dissolve in the gastrointestinal (G.I.) tract in a predictably delayed manner.
- the hydrophilicity and water swellability of these polymers cause the drug-containing matrices to swell in size in the gastric cavity due to ingress of water, and to become slippery, which further promotes their retention in the stomach.
- the release rate of a drug from the matrix is primarily dependent upon the rate at which the drug diffuses from the swollen polymer, which in turn is related to the solubility and dissolution rate of the drug, the particle size and the drug concentration in the matrix.
- the matrix particles maintain their integrity over at least a substantial period of time, i.e. , at least 90% and preferably over 100% of the dosing period. The particles will then slowly dissolve or decompose. In most cases, complete dissolution or decomposition will occur within 8 to 10 hours after the intended dosing period.
- Preferred alkyl-substituted cellulose derivatives are those containing alkyl groups of
- one class of preferred alkyl-substituted celluloses includes those whose viscosity is within the range of about 100 to about 6,500 centipoise as a 2% aqueous solution at 20°C.
- Another class includes those whose viscosity is within the range of about 1,000 to about 4,000 centipoise as a 1 % aqueous solution at 20°C.
- Particularly preferred alkyl-substituted celluloses are hydroxyethylcellulose and hydroxypropylcellulose.
- a presently preferred hydroxyethylcellulose is NATRASOL ® 250HX NF (National Formulary), available from Aqualon Company, Wilmington, Delaware, USA.
- Polyalkylene oxides of greatest utility in this invention are those having the properties described above for alkyl-substituted cellulose polymers.
- a particularly preferred polyalkylene oxide is polyethylene oxide), which term is used herein to denote a linear polymer of unsubstituted ethylene oxide.
- Preferred poly(ethylene oxide)s are those with a weight-average molecular weight within the range of about 2 x IO 6 to about
- Two presently preferred polyethylene oxide)s are POLYOX ® NF, grade WSR Coagulant, molecular weight 5 million, and grade WSR 303, molecular weight 7 million, both products of Union Carbide Chemicals and Plastics Company Inc. of Danbury, Connecticut, USA, with a weight-average molecular weight of about 5 x IO 6 .
- the drug is preferably dispersed homogeneously in the polymeric matrix, although this is not a requirement of the present invention.
- the weight ratio of drug to polymer is not critical and may vary.
- the particles are preferably consolidated into a packed mass for ingestion, even though they will separate into individual particles once ingested.
- Conventional methods can be used for consolidating the particles in this manner.
- the particles can be placed in gelatin capsules known in the art as "hard-filled” capsules and "soft-elastic" capsules.
- the compositions of these capsules and procedures for forming them are known among those skilled in drug formulations.
- the encapsulating material should be highly soluble so that the particles are rapidly dispersed in the stomach after the capsule is ingested.
- One presently preferred dosage form is a size 0 gelatin capsule containing either two or three pellets of drug- impregnated polymer.
- the pellets are cylindrically shaped, 6 mm in diameter and 10.5 mm in length.
- the pellets are again cylindrically shaped, 6 mm in diameter and 7 mm in length.
- the pellets are cylindrical, 7.5 mm in diameter and 11.75 mm in length.
- the pellets are cylindrical, 7.5 mm in diameter and 4.8 mm in length.
- serotonin receptor antagonists are a known class of compounds. Examples are granisetron, dolasetron, ondansetron, tropisetron, zacopride,nic acid, ketanserin, methysergide,
- 2-bromo-N,N-diethyl-D-lysergamide, pindobind, nefazodone, amesergide, and octreotide acetate are particularly preferred.
- fatty acids and their salts those that are preferred are straight-chain saturated fatty acids, particularly the C 12 -C 14 acids.
- Preferred salts are the sodium and potassium salts, with sodium particularly preferred.
- lauric acid, tridecylic acid, myristic acid, and the sodium salts of these acids are particularly preferred.
- the fed-mode inducing agent is incorporated in the dosage form of this invention in such a manner that it induces the fed mode immediately upon ingestion. Accordingly, at least a substantial portion of the agent, and in many cases all of it, is released immediately upon contact with the gastric fluid. This result is preferably achieved by placing most, and preferably all, of the fed-mode inducing agent outside the water-swellable matrix rather than dispersing it in the matrix in the manner that the drug is dispersed.
- the agent is preferably layered or coated in solid form over the matrix, formed into one or more laminae of a laminated tablet in which the drug-impregnated matrix forms one or more other laminae, or added in powder form to a capsule that also contains the particles of water-swellable matrix.
- the solid coating or layer preferably consists of the fed-mode inducing agent retained in a water-soluble matrix that rapidly disintegrates upon contact with the gastric fluid, thereby releasing the agent into the fluid.
- materials for such a matrix are sodium carboxymefhylcellulose, sodium starch glycolate, crospovidone, hydroxypropyl ⁇ cellulose, and substituted hydroxypropylcellulose.
- Sodium starch glycolate is particularly preferred.
- the proportion of the fed-mode inducing agent in the water-soluble matrix can vary widely and is not critical. In most cases, however, best results will be achieved with a weight ratio of agent to total water-soluble matrix in the dosage form ranging from about 0.5:8 to about 3:5, and preferably from about 1 :8 to about 2:8.
- serotonin receptor antagonists are themselves therapeutic drugs, they can serve both their therapeutic function and the fed-mode inducement function when included in a dosage form of this invention. Accordingly, in dosage forms of this invention that include serotonin receptor antagonists the antagonists are preferably not immediately releasable upon contact with the gastric fluid, but held within the water-swellable matrix so that they are released at a controlled rate. The antagonist thus provides the benefits of gastric retention as well as its intended therapeutic function.
- the amount of fed-mode inducing agent will vary depending on the type of agent used. In general, the amount will be selected as that which will induce and maintain the fed mode long enough for the particles of water-swellable polymer to reach a size which is large enough to be retained in the stomach in either the fed or fasting modes. Preferred amounts are within the range of about 50 mg to about 200 mg, and most preferably about 75 mg to about 150 mg, per single oral dosage form.
- the dosage forms of this invention are effective for administering drugs of limited solubility in gastric fluid.
- the drugs include those that are capable of acting locally within the gastrointestinal tract or systemically by absorption into circulation by the gastrointestinal mucosa.
- Preferred drugs are solid and of limited water solubility to avoid rapid diffusion of the drug from the water-swellable polymer matrix. To achieve this, it is preferred that portions of the drug be retained in the matrix in solid form for at least about two hours. Conversely, these drugs must be sufficiently soluble to permit the diffusion required to achieve the desired therapy. Thus, the solubility of the drugs should be such that they diffuse from the particles at a rate fast enough to provide an effective level of therapy yet slow enough to extend the treatment over the desired duration. In most cases, best results will be achieved with drugs whose solubility (determined in water at 37 °C) lies within the range of about 0.01 % to about 35% by weight, and preferably from about 0.1 % to about 5 % by weight.
- the gastric retentive system of this invention is useful as a means of administering drugs to eradicate Helicobacter pylori from the submucosal tissue of the gastrointestinal tract, particularly the stomach.
- Such use of this gastric retentive system improves the effectiveness of these drugs against stomach and duodenal ulcers as well as gastritis and esophagitis, and for reducing the risk of gastric carcinoma.
- Drugs and drug combinations suggested for these indications include bismuth salts such as bismuth subsalicylate and bismuth citrate, metronidazole, and amoxycillin, other antibiotics such as clarithromycin, thiamphenicol, tetracycline, neomycin or erythromycin, and combinations of these drugs.
- Preferred drugs for this indication are clarithromycin plus omeprazole, a bismuth salt plus metronidazole, amoxycillin plus metronidazole, and amoxycillin or a bismuth salt plus
- the invention can also be used with conventional ulcer treatment drugs such as the H-2 antagonists cimetidine or ranitidine, or a non-systemic antacid such as calcium carbonate.
- An antacid is often desirable as an additive to accompany agents that function most effectively in an anacidic stomach.
- This invention is also of particular value in the administration of drugs such as peptides and proteins that are labile upon exposure to gastric pH or gastric enzymes. These drugs and others of a similarly large molecular size are most efficiently absorbed in the region extending from the lower stomach through the duodenum to the upper part of the small intestine.
- the formulations of this invention physically protect the undissolved portion of the drug within the water-swellable matrix until the drug dissolves and is thereby released.
- Therapeutic agents that otherwise require administration by injection can thus provide effective results when administered orally.
- examples of such agents are calcitonin, calcitriol and insulin.
- Further examples of therapeutic agents that are not efficiently absorbed from the G.I. tract and that will therefore benefit from this invention are captopril, simvastitin, cyclosporins, acyclovir, cephalosporins, interleukins, nitrofurantoin, and the ergot alkaloids.
- the present invention offers both a reduction in side effects associated with the drug and the ability to achieve efficacy with less frequent administration.
- therapies in which this is useful are as follows: (1) A reduction in angioedema and agranulocytoses, which are side effects arising from the administration of angiotensin-converting enzyme inhibitors such as enalapril maleate and captopril;
- Calcium channel blockers such as verapamil, diltiazem, nifedipine, or nicardipine, for example, can be administered with controlled delivery and gastric retention to extend their effects through the night and thereby alleviate early morning hypertension, the cause of many heart attacks. The frequency of administration can also be reduced to a single daily dose.
- Gastrointestinal prokinetic agents such as cisapride will similarly benefit from gastric retention.
- the invention also enhances the treatment of gastroesphageal reflux disease by providing prolonged, localized effects of agents such as pentagastrin, PG-F2, and metaclopramide that improves the competency of lower esophageal sphincter (LES) muscles.
- H-2 antagonists or calcium carbonate for ulcer treatment and prevention include H-2 antagonists or calcium carbonate for ulcer treatment and prevention; non-steroidal anti-inflammatory agents (NSAIDS) such as indomethacin, ibuprofen, naproxen and piroxicam; steroids such as prednisone, prednisolone and dexamethasone; other NSAIDS such as diclofenac and ketorolac; acyclovir for the treatment of viral diseases such as herpes; tamoxifen for treatment of cancer; chlorpheniramine maleate for allergic disorders; potassium chloride for potassium supplementation, and peptides or other labile molecules such as protease inhibitors for treatment of AIDS. Still further drugs will be apparent to those skilled in pharmacology .
- NSAIDS non-steroidal anti-inflammatory agents
- steroids such as prednisone, prednisolone and dexamethasone
- other NSAIDS such as diclofenac and ketorolac
- the particulate drug/polymer mixture or drug-impregnated polymer matrix can be prepared by various conventional mixing and comminution techniques readily apparent to those skilled in the chemistry of drug formulations. Examples such techniques are as follows:
- lubricants When particles are made by direct compression, the addition of lubricants may be helpful and sometimes important to promote powder flow and to prevent capping of the particle (breaking off of a portion of the sphere) when the pressure is relieved.
- Useful lubricants are magnesium stearate (in a concentration of from 0.25 % to 3% by weight, preferably less than 1 % by weight, in the powder mix), and hydrogenated vegetable oil (preferably hydrogenated and refined triglycerides of stearic and palmitic acids at about 1 % to 5 % by weight, most preferably about 2% by weight. Additional excipients may be added to enhance powder flowability and reduce adherence.
- the multi-particle dosage form of this invention permits different drugs to be placed in different matrix particles, each particle individually formulated to provide the release rate and duration that are optimal for the particular drug carried by that particle. This can be done by varying the matrix composition, the particle size, the particle molecular weights, or any other characteristic that affects the release rate and duration.
- the number of particles carrying individual drugs can also be varied among the different drugs. For example, a capsule made from three particles may contain two particles carrying one drug and one particle carrying the other drug.
- Examples of drug combinations for which the formulations of this invention are useful are norethindrone plus ethinyl estradiol, a combination useful for fertility control, acetaminophen plus codeine (a potent analgesic combination), captopril plus hydrochlorthiazide (a useful cardiovascular combination), and clarithromycin plus omeprazole (for the eradication of H. pylori).
- each ingredient can be individually formulated to achieve a release rate that is optimal for the pharmacokinetics and biological activity of each drug.
- This invention is also useful as a means of co-administering drugs that cannot otherwise be combined in a single dosage form due to their chemical incompatibility.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32903/97A AU3290397A (en) | 1996-06-10 | 1997-05-29 | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66358896A | 1996-06-10 | 1996-06-10 | |
US08/663,588 | 1996-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997047285A1 true WO1997047285A1 (en) | 1997-12-18 |
Family
ID=24662476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/009245 WO1997047285A1 (en) | 1996-06-10 | 1997-05-29 | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3290397A (en) |
WO (1) | WO1997047285A1 (en) |
Cited By (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032091A1 (en) * | 1997-12-22 | 1999-07-01 | Astrazeneca Ab | Oral pharmaceutical extended release dosage form |
EP0966966A2 (en) * | 1998-06-05 | 1999-12-29 | Bristol-Myers Squibb Company | Nefazodone dosage form |
FR2784583A1 (en) * | 1998-10-16 | 2000-04-21 | Synthelabo | Tablets swelling and liberating carbon dioxide to prolong residence time in stomach, contain active material, liberation modifier, carbonate and hydrophilic polymer |
WO2000025790A1 (en) * | 1998-11-02 | 2000-05-11 | Alza Corporation | Controlled delivery of antidepressants |
EP1090638A1 (en) * | 1999-10-08 | 2001-04-11 | Sanofi-Synthelabo | Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea |
WO2001032217A2 (en) * | 1999-11-02 | 2001-05-10 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US6280745B1 (en) | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
JP2001526213A (en) * | 1997-12-22 | 2001-12-18 | アストラゼネカ・アクチエボラーグ | Oral drug pulse release dosage form |
WO2001097783A1 (en) * | 2000-06-20 | 2001-12-27 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
EP1428535A1 (en) * | 1998-11-02 | 2004-06-16 | ALZA Corporation | Controlled delivery of antidepressants |
WO2006094782A2 (en) * | 2005-03-08 | 2006-09-14 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition for oral application with controlled release of active substances |
WO2007074406A2 (en) | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
US7838028B2 (en) | 2001-03-31 | 2010-11-23 | Jagotec Ag | Pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, and respective processes of producing same and a cup-shaped envelope of same |
US7838027B2 (en) | 2003-10-01 | 2010-11-23 | Wyeth Llc | Pantoprazole multiparticulate formulations |
EP2286817A2 (en) | 2003-01-13 | 2011-02-23 | Edusa Pharmaceuticals, Inc | Method of treating functional bowel disorders |
WO2012021629A2 (en) | 2010-08-11 | 2012-02-16 | Philadelphia Health & Education Corporation | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
WO2012078633A2 (en) | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
US8303987B2 (en) | 2001-04-11 | 2012-11-06 | Novartis Ag | Pharmaceutical compositions comprising fluvastatin |
US8333991B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US20130011444A1 (en) * | 2011-07-09 | 2013-01-10 | Syntrix Biosystems, Inc. | Compositions and methods for overcoming resistance to tramadol |
US8440232B2 (en) | 2001-10-25 | 2013-05-14 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
WO2014015157A2 (en) | 2012-07-19 | 2014-01-23 | Philadelphia Health & Education Corporation | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
WO2014107663A2 (en) | 2013-01-07 | 2014-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
WO2015080943A1 (en) | 2013-11-26 | 2015-06-04 | Yale University | Novel cell-penetrating compositions and methods using same |
WO2015157262A1 (en) | 2014-04-07 | 2015-10-15 | Women & Infants Hospital Of Rhode Island | Novel 7-Dehydrocholesterol Derivatives and Methods Using Same |
WO2016028753A1 (en) | 2014-08-20 | 2016-02-25 | Yale University | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
US9421178B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
WO2016187408A1 (en) | 2015-05-19 | 2016-11-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
WO2017003822A1 (en) | 2015-06-30 | 2017-01-05 | Galleon Pharmaceuticals, Inc. | Novel breathing control modulating compounds, and methods of making and using same |
US9539328B2 (en) | 2011-05-17 | 2017-01-10 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9629837B2 (en) | 2011-05-17 | 2017-04-25 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
EP3158995A1 (en) | 2012-08-09 | 2017-04-26 | Dynamis Therapeutics, Inc. | Meglumine for reducing or preventing the increase of triglyceride levels |
WO2017075145A1 (en) | 2015-10-28 | 2017-05-04 | Yale University | Quinoline amides and methods of using same |
EP3195896A1 (en) | 2009-05-05 | 2017-07-26 | Board of Regents, The University of Texas System | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
WO2017190001A1 (en) | 2016-04-29 | 2017-11-02 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
WO2018026764A1 (en) | 2016-08-01 | 2018-02-08 | University Of Rochester | Nanoparticles for controlled release of anti-biofilm agents and methods of use |
WO2018027024A1 (en) | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
WO2018045229A1 (en) | 2016-09-01 | 2018-03-08 | Mebias Discovery Llc | Substituted ureas and methods of making and using same |
WO2018085619A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma, Inc. | Substituted pyridinone-containing tricyclic compounds, and methods using same |
US9988376B2 (en) | 2013-07-03 | 2018-06-05 | Glaxosmithkline Intellectual Property Development Limited | Benzothiophene derivatives as estrogen receptor inhibitors |
US9993514B2 (en) | 2013-07-03 | 2018-06-12 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2018172852A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
WO2018195084A1 (en) | 2017-04-17 | 2018-10-25 | Yale University | Compounds, compositions and methods of treating or preventing acute lung injury |
US10166207B2 (en) | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
WO2019023621A1 (en) | 2017-07-28 | 2019-01-31 | Yale University | Anticancer Drugs and Methods of Making and Using Same |
US10258615B2 (en) | 2013-12-09 | 2019-04-16 | Thomas Jefferson University | Methods of treating a neurodegenerative disease in a mammal in need thereof |
WO2019104316A1 (en) | 2017-11-27 | 2019-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, compositions, and methods for treating and/or preventing periodontal disease |
WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
WO2019147753A1 (en) | 2018-01-24 | 2019-08-01 | The Rockefeller University | Antibacterial compounds, compositions thereof, and methods using same |
WO2019231739A1 (en) | 2018-05-29 | 2019-12-05 | Cersci Therapeutics, Inc. | Compounds for pain treatment, compositions comprising same, and methods of using same |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
EP3613861A1 (en) | 2013-07-02 | 2020-02-26 | EcoPlanet Environmental LLC | Volatile organic compound formulations having antimicrobial activity |
US10597368B2 (en) | 2015-05-08 | 2020-03-24 | Brown University | Syringolin analogues and methods of making and using same |
WO2020074944A1 (en) | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
WO2020123674A1 (en) | 2018-12-12 | 2020-06-18 | Arbutus Biopharma Corporation | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
WO2020159565A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent |
WO2020159588A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent |
WO2020157362A1 (en) | 2019-01-30 | 2020-08-06 | Sanifit Therapeutics, S.A. | Inositol phosphate compounds for use in increasing tissular perfusion |
US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
WO2020227603A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
WO2021252549A1 (en) | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
US11426409B2 (en) | 2017-09-08 | 2022-08-30 | The Regents Of The University Of Colorado | Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers |
EP4079322A1 (en) | 2015-11-20 | 2022-10-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
EP4219486A1 (en) | 2017-01-19 | 2023-08-02 | Temple University of the Commonwealth System of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
WO2024023359A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2163648A (en) * | 1984-08-03 | 1986-03-05 | Nippon Shinyaku Co Ltd | Slow release preparations |
US4659558A (en) * | 1982-03-22 | 1987-04-21 | Alza Corporation | Oral delivery system comprising a plurality of tiny pills for delivering drug in the stomach and intestine |
EP0272876A2 (en) * | 1986-12-17 | 1988-06-29 | Glaxo Group Limited | Use of heterocyclic derivatives for the manufacture of medicaments |
EP0391462A1 (en) * | 1989-04-05 | 1990-10-10 | Janssen Pharmaceutica N.V. | Synergistic compositions containing ketanserin |
EP0477625A1 (en) * | 1990-09-17 | 1992-04-01 | E.R. SQUIBB & SONS, INC. | Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
EP0497977A1 (en) * | 1989-10-26 | 1992-08-12 | Nippon Shinyaku Company, Limited | Gastric preparation |
WO1993018755A1 (en) * | 1992-03-25 | 1993-09-30 | Depomed Systems, Incorporated | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
-
1997
- 1997-05-29 WO PCT/US1997/009245 patent/WO1997047285A1/en active Application Filing
- 1997-05-29 AU AU32903/97A patent/AU3290397A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659558A (en) * | 1982-03-22 | 1987-04-21 | Alza Corporation | Oral delivery system comprising a plurality of tiny pills for delivering drug in the stomach and intestine |
GB2163648A (en) * | 1984-08-03 | 1986-03-05 | Nippon Shinyaku Co Ltd | Slow release preparations |
EP0272876A2 (en) * | 1986-12-17 | 1988-06-29 | Glaxo Group Limited | Use of heterocyclic derivatives for the manufacture of medicaments |
EP0391462A1 (en) * | 1989-04-05 | 1990-10-10 | Janssen Pharmaceutica N.V. | Synergistic compositions containing ketanserin |
EP0497977A1 (en) * | 1989-10-26 | 1992-08-12 | Nippon Shinyaku Company, Limited | Gastric preparation |
EP0477625A1 (en) * | 1990-09-17 | 1992-04-01 | E.R. SQUIBB & SONS, INC. | Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
WO1993018755A1 (en) * | 1992-03-25 | 1993-09-30 | Depomed Systems, Incorporated | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
Cited By (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001526213A (en) * | 1997-12-22 | 2001-12-18 | アストラゼネカ・アクチエボラーグ | Oral drug pulse release dosage form |
US6605303B1 (en) | 1997-12-22 | 2003-08-12 | Astrazeneca Ab | Oral pharmaceutical extended release dosage form |
JP4907765B2 (en) * | 1997-12-22 | 2012-04-04 | アストラゼネカ・アクチエボラーグ | Oral pharmaceutical pulse release dosage form |
CZ299228B6 (en) * | 1997-12-22 | 2008-05-21 | Astrazeneca Ab | Oral pharmaceutical dosage form with prolonged release |
WO1999032091A1 (en) * | 1997-12-22 | 1999-07-01 | Astrazeneca Ab | Oral pharmaceutical extended release dosage form |
JP2001526211A (en) * | 1997-12-22 | 2001-12-18 | アストラゼネカ・アクチエボラーグ | Oral extended release pharmaceutical dosage form |
JP4865945B2 (en) * | 1997-12-22 | 2012-02-01 | アストラゼネカ・アクチエボラーグ | Oral extended release pharmaceutical dosage form |
US6280745B1 (en) | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
EP0966966A3 (en) * | 1998-06-05 | 2000-02-09 | Bristol-Myers Squibb Company | Nefazodone dosage form |
EP0966966A2 (en) * | 1998-06-05 | 1999-12-29 | Bristol-Myers Squibb Company | Nefazodone dosage form |
US6143325A (en) * | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
FR2784583A1 (en) * | 1998-10-16 | 2000-04-21 | Synthelabo | Tablets swelling and liberating carbon dioxide to prolong residence time in stomach, contain active material, liberation modifier, carbonate and hydrophilic polymer |
WO2000023045A1 (en) * | 1998-10-16 | 2000-04-27 | Sanofi-Synthelabo | Pharmaceutical composition with gastric residence and controlled release |
US6861072B1 (en) | 1998-10-16 | 2005-03-01 | Sanofi-Synthelabo | Pharmaceutical composition with gastric residence and controlled release |
US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
WO2000025790A1 (en) * | 1998-11-02 | 2000-05-11 | Alza Corporation | Controlled delivery of antidepressants |
EP1428535A1 (en) * | 1998-11-02 | 2004-06-16 | ALZA Corporation | Controlled delivery of antidepressants |
KR100734193B1 (en) * | 1998-11-02 | 2007-07-02 | 알자 코포레이션 | Controlled delivery of antidepressants |
EP1090638A1 (en) * | 1999-10-08 | 2001-04-11 | Sanofi-Synthelabo | Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea |
WO2001026657A1 (en) * | 1999-10-08 | 2001-04-19 | Sanofi-Synthelabo | Use of (r)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea |
WO2001032217A3 (en) * | 1999-11-02 | 2002-07-18 | Depomed Inc | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
EP1790334A2 (en) * | 1999-11-02 | 2007-05-30 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
WO2001032217A2 (en) * | 1999-11-02 | 2001-05-10 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
EP1790334A3 (en) * | 1999-11-02 | 2008-02-20 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
US7405238B2 (en) | 1999-11-02 | 2008-07-29 | Depomed Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
US6432447B2 (en) | 2000-04-13 | 2002-08-13 | Novartis Ag | Organic compounds |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
WO2001097783A1 (en) * | 2000-06-20 | 2001-12-27 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US7838028B2 (en) | 2001-03-31 | 2010-11-23 | Jagotec Ag | Pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, and respective processes of producing same and a cup-shaped envelope of same |
US8303987B2 (en) | 2001-04-11 | 2012-11-06 | Novartis Ag | Pharmaceutical compositions comprising fluvastatin |
US8529955B2 (en) | 2001-10-25 | 2013-09-10 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8409613B2 (en) | 2001-10-25 | 2013-04-02 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US8580303B2 (en) | 2001-10-25 | 2013-11-12 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US8440232B2 (en) | 2001-10-25 | 2013-05-14 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8475813B2 (en) | 2001-10-25 | 2013-07-02 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8802157B2 (en) | 2001-10-25 | 2014-08-12 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage form |
US8333992B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US8333991B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
EP2286817A2 (en) | 2003-01-13 | 2011-02-23 | Edusa Pharmaceuticals, Inc | Method of treating functional bowel disorders |
US7838027B2 (en) | 2003-10-01 | 2010-11-23 | Wyeth Llc | Pantoprazole multiparticulate formulations |
WO2006094782A3 (en) * | 2005-03-08 | 2007-01-04 | Klosterfrau Mcm Vetrieb Gmbh | Composition for oral application with controlled release of active substances |
WO2006094782A2 (en) * | 2005-03-08 | 2006-09-14 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition for oral application with controlled release of active substances |
WO2007074406A2 (en) | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
EP3195896A1 (en) | 2009-05-05 | 2017-07-26 | Board of Regents, The University of Texas System | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
WO2012021629A2 (en) | 2010-08-11 | 2012-02-16 | Philadelphia Health & Education Corporation | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
WO2012078633A2 (en) | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
US9629837B2 (en) | 2011-05-17 | 2017-04-25 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US9539328B2 (en) | 2011-05-17 | 2017-01-10 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9808432B2 (en) | 2011-07-09 | 2017-11-07 | Syntrix Biosystems Inc. | Methods for overcoming resistance to tramadol |
US10702485B2 (en) * | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
US9717701B2 (en) | 2011-07-09 | 2017-08-01 | Syntrix Biosystems Inc. | Compositions for overcoming resistance to tramadol |
US9717700B2 (en) | 2011-07-09 | 2017-08-01 | Syntrix Biosystems Inc. | Methods for overcoming resistance to tramadol |
US20130011444A1 (en) * | 2011-07-09 | 2013-01-10 | Syntrix Biosystems, Inc. | Compositions and methods for overcoming resistance to tramadol |
US10512621B2 (en) | 2011-12-02 | 2019-12-24 | Synchroneuron, Inc. | Methods of treating posttraumatic stress disorder with acamprosate salts |
US9421178B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9421179B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9427420B2 (en) | 2011-12-02 | 2016-08-30 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
EP3312160A1 (en) | 2011-12-21 | 2018-04-25 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
WO2014015157A2 (en) | 2012-07-19 | 2014-01-23 | Philadelphia Health & Education Corporation | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
EP3158995A1 (en) | 2012-08-09 | 2017-04-26 | Dynamis Therapeutics, Inc. | Meglumine for reducing or preventing the increase of triglyceride levels |
EP3378472A1 (en) | 2012-08-09 | 2018-09-26 | Dynamis Therapeutics, Inc. | Combinations of meglumine |
EP3756669A1 (en) | 2013-01-07 | 2020-12-30 | The Trustees of the University of Pennsylvania | Compositions for use for treating cutaneous t cell lymphoma |
WO2014107663A2 (en) | 2013-01-07 | 2014-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
US10166207B2 (en) | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
EP3613861A1 (en) | 2013-07-02 | 2020-02-26 | EcoPlanet Environmental LLC | Volatile organic compound formulations having antimicrobial activity |
US9988376B2 (en) | 2013-07-03 | 2018-06-05 | Glaxosmithkline Intellectual Property Development Limited | Benzothiophene derivatives as estrogen receptor inhibitors |
US9993514B2 (en) | 2013-07-03 | 2018-06-12 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2015080943A1 (en) | 2013-11-26 | 2015-06-04 | Yale University | Novel cell-penetrating compositions and methods using same |
US10258615B2 (en) | 2013-12-09 | 2019-04-16 | Thomas Jefferson University | Methods of treating a neurodegenerative disease in a mammal in need thereof |
US11369596B2 (en) | 2013-12-09 | 2022-06-28 | Thomas Jefferson University | Methods of treating a neurodegenerative disease in a mammal in need thereof |
US11034719B2 (en) | 2014-04-07 | 2021-06-15 | University Of Rochester | 7-dehydrocholesterol derivatives and methods using same |
WO2015157262A1 (en) | 2014-04-07 | 2015-10-15 | Women & Infants Hospital Of Rhode Island | Novel 7-Dehydrocholesterol Derivatives and Methods Using Same |
US10683324B2 (en) | 2014-04-07 | 2020-06-16 | University Of Rochester | 7-dehydrocholesterol derivatives and methods using same |
WO2016028753A1 (en) | 2014-08-20 | 2016-02-25 | Yale University | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
US10597368B2 (en) | 2015-05-08 | 2020-03-24 | Brown University | Syringolin analogues and methods of making and using same |
WO2016187408A1 (en) | 2015-05-19 | 2016-11-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
WO2017003822A1 (en) | 2015-06-30 | 2017-01-05 | Galleon Pharmaceuticals, Inc. | Novel breathing control modulating compounds, and methods of making and using same |
WO2017075145A1 (en) | 2015-10-28 | 2017-05-04 | Yale University | Quinoline amides and methods of using same |
EP4079322A1 (en) | 2015-11-20 | 2022-10-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
WO2017190001A1 (en) | 2016-04-29 | 2017-11-02 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
WO2018026764A1 (en) | 2016-08-01 | 2018-02-08 | University Of Rochester | Nanoparticles for controlled release of anti-biofilm agents and methods of use |
WO2018027024A1 (en) | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
WO2018045229A1 (en) | 2016-09-01 | 2018-03-08 | Mebias Discovery Llc | Substituted ureas and methods of making and using same |
WO2018085619A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma, Inc. | Substituted pyridinone-containing tricyclic compounds, and methods using same |
EP4219486A1 (en) | 2017-01-19 | 2023-08-02 | Temple University of the Commonwealth System of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
WO2018172852A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
WO2018195084A1 (en) | 2017-04-17 | 2018-10-25 | Yale University | Compounds, compositions and methods of treating or preventing acute lung injury |
WO2019023621A1 (en) | 2017-07-28 | 2019-01-31 | Yale University | Anticancer Drugs and Methods of Making and Using Same |
US11426409B2 (en) | 2017-09-08 | 2022-08-30 | The Regents Of The University Of Colorado | Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers |
US11629159B2 (en) | 2017-10-09 | 2023-04-18 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11149044B2 (en) | 2017-10-09 | 2021-10-19 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11447510B2 (en) | 2017-10-09 | 2022-09-20 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11180517B2 (en) | 2017-10-09 | 2021-11-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11851451B2 (en) | 2017-10-09 | 2023-12-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10947257B2 (en) | 2017-10-09 | 2021-03-16 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10954259B1 (en) | 2017-10-09 | 2021-03-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11505564B2 (en) | 2017-10-09 | 2022-11-22 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
WO2019104316A1 (en) | 2017-11-27 | 2019-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, compositions, and methods for treating and/or preventing periodontal disease |
WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
WO2019147753A1 (en) | 2018-01-24 | 2019-08-01 | The Rockefeller University | Antibacterial compounds, compositions thereof, and methods using same |
WO2019231739A1 (en) | 2018-05-29 | 2019-12-05 | Cersci Therapeutics, Inc. | Compounds for pain treatment, compositions comprising same, and methods of using same |
US10973838B2 (en) | 2018-10-11 | 2021-04-13 | Sanifit Therapeutics S.A. | IP and IP analogs dosage regimens for the treatment of ectopic calcifications |
WO2020074944A1 (en) | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
WO2020123674A1 (en) | 2018-12-12 | 2020-06-18 | Arbutus Biopharma Corporation | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
WO2020157362A1 (en) | 2019-01-30 | 2020-08-06 | Sanifit Therapeutics, S.A. | Inositol phosphate compounds for use in increasing tissular perfusion |
WO2020159565A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent |
WO2020159588A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent |
US11738035B2 (en) | 2019-04-17 | 2023-08-29 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
WO2020227603A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
WO2021094331A1 (en) | 2019-11-11 | 2021-05-20 | Sanifit Therapeutics, S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
WO2021252549A1 (en) | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
WO2022129148A1 (en) | 2020-12-15 | 2022-06-23 | Sanifit Therapeutics, S.A. | Processes for the preparation of soluble salts of inositol phosphates |
EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
WO2022162206A1 (en) | 2021-01-29 | 2022-08-04 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds |
EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
WO2024023359A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Also Published As
Publication number | Publication date |
---|---|
AU3290397A (en) | 1998-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997047285A1 (en) | Gastric-retentive oral controlled drug delivery system with enhanced retention properties | |
AU781718B2 (en) | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | |
EP0632720B1 (en) | Hydroxyethylcellulose-based sustained-release oral drug dosage froms | |
US5582837A (en) | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms | |
EP0941071B1 (en) | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter | |
CA2412671C (en) | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms | |
AU2003207755B2 (en) | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs | |
US6632451B2 (en) | Delayed total release two pulse gastrointestinal drug delivery system | |
CA2409999C (en) | Optical polymer mixtures for gastric retentive tablets | |
KR100618234B1 (en) | Dosage forms comprising porous particles | |
AU2001239893A1 (en) | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms | |
AU2002337974A1 (en) | Optimal polymer mixtures for gastric retentive tablets | |
EP1322313A2 (en) | Controlled release formulations for oral administration | |
WO2009038340A1 (en) | Pharmaceutical composition of artemisia extract using gastro-retentive drug delivery system and its oral sustained release formulation | |
WO2004037228A1 (en) | Sustained release compositions containing alfuzosin | |
KR100545480B1 (en) | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98501638 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |